浆膜腔脱落细胞学检查与肿瘤标志物水平相关性探讨

目的探讨在判断恶性肿瘤侵犯浆膜时脱落细胞学检查与肿瘤标志物水平的关系。方法选择158例有明确恶性肿瘤病史的患者,依据细胞学检查结果分为检出恶性细胞组和未检出恶性细胞组,并对其血清及浆膜腔积液肿瘤标志物水平进行检测分析。结果检出恶性细胞组浆膜腔积液癌胚抗原(CEA)、糖类抗原19-9(CA19-9)和糖类抗原125(CA125)水平分别为294.85(6.03～1 000.00)μg/L、367.00(8.82～1 000.00)kU/L、3 435.00(922.20～5 000.00)kU/L,血清分别为9.98(0.48～1 000.00)μg/L、23.76(0.66～1 000.00)kU/L、90.55(47.21～1 796.00)kU/L,二者比较差异有统计学意义(P均<0.05);未检出恶性细胞组浆膜腔积液CEA、CA19-9和CA125水平分别为1.67(0.20～373.08)μg/L、13.13(4.34～725.10)kU/L、11.23(6.83～172.50)kU/L,血清分别为2.69(0.20～110.90)μg/L、31.22(6.07～1 000.00)kU/L、19.32(17.20～491.10)kU/L,二者比较差异无统计学意义(P均>0.05);检出恶性细胞组与未检出恶性细胞组浆膜腔积液CEA、CA19-9和CA125水平比较差异有统计学意义(P均<0.01)。检出恶性细胞组中有核细胞分类淋巴细胞>50%者占61.4%(70/114),巨噬细胞>25%者占42.1%(48/114)。结论恶性肿瘤侵犯浆膜可引起浆膜腔积液肿瘤标志物水平增高及淋巴细胞和巨噬细胞的聚集。     

血清CA125在卵巢癌诊断及预测分期中的应用价值

目的探讨血清CA125在卵巢癌诊断及预测分期中的应用价值。方法我院妇产科2001年1月—2010年10月收治卵巢癌病人520例,测定其血清CA125水平,并分析其与卵巢癌病理组织学类型、临床分期的关系。结果 520例卵巢癌病人中上皮性卵巢癌组血清CA125水平与生殖细胞肿瘤组及性索间质肿瘤组比较明显增高（F=9.466,P〈0.01）;上皮性卵巢癌组中浆液性囊腺癌CA125水平与黏液性腺癌及透明细胞癌相比明显增高（F=7.399,P〈0.01）;Ⅲ～Ⅳ期组CA125的水平明显高于Ⅰ～Ⅱ期组（F=54.720,t=7.852,P〈0.01）;低分化组血清CA125水平明显高于高、中分化组（F=47.031,t=6.880,P〈0.01）;血清CA125含量〉46.36kU/L时,上皮性卵巢癌的诊断价值最高,对应的诊断灵敏度为82.6%,特异度为61.8%;当CA125〉150kU/L时,晚期病人诊断灵敏度、特异度及准确率分别为85.66%、59.22%及75.48%,此时对卵巢癌晚期诊断意义大。结论血清CA125对上皮性卵巢癌的诊断具有较高价值,尤其是上皮性浆液性囊腺癌病人血清CA125水平升高明显;晚期（Ⅲ～Ⅳ期）以及低分化病人CA125水平较高;CA125诊断价值的最佳临界点高于普遍认为的阳性诊断标准,当CA125〉150kU/L时,对晚期病人诊断意义较大。     

CEA、CA199、CA125在良恶性浆膜腔积液性质鉴别中的价值

目的 评估浆膜腔积液和血清中CEA、CA199、CA125在鉴别良恶性浆膜腔积液中的价值.方法 应用电化学发光法（ECL）分别测定80例浆膜腔积液发现癌细胞的患者、80例浆膜腔积液未发现癌细胞患者的血清,以及浆膜腔积液中CEA、CA199、CA125水平,并加以分析.结果 恶性浆膜腔积液患者的浆膜腔积液和血清中的CEA、CA199、CA125水平明显高于良性浆膜腔积液患者,差异均有统计学意义（P＜0.05）;同时,恶性浆膜腔积液患者CEA、CA199、CA125在积液中的水平高于其血清中的水平,差异也具有统计学意义（P＜0.05）.ROC曲线表明,恶性浆膜腔积液中的CEA、CA199、CA125的ROC曲线下面积（AUC）分别为0.929、0.926、0.854.结论 浆膜腔积液中的CEA、CA199、CA125水平对判断良恶性浆膜腔积液性质具有重要的参考价值.     

血清CA125水平检测在妇科疾病中的临床应用

[目的] 探讨血清CA125水平在某些妇科疾病中的升高情况及临床应用价值.[方法] 采用电化学免疫发光法检测196例妇科疾病患者与100名正常人血清CA125水平.[结果] 血清CA125水平在卵巢癌、卵巢良性肿瘤、子宫肌瘤、子宫腺肌症、盆腔炎有增高,平均值分别为402.65、146.40、57.62、107.50、56.14 kU/L,妇科疾病各组阳性检出率分别为81.03%、19.73%、40.0%、72.73%、35.0%,其中卵巢癌患者血清CA125水平与卵巢良性肿瘤相比,差异具有高度显著性（P〈0.01）;子宫肌瘤与子宫腺肌症血清CA125水平差异具有显著性（P〈0.05）.如以CA125〈35 kU/L和CA125〈65kU/L为临界值诊断卵巢癌,其特异性分别为80.2%、92.1%,两者具有统计学差异（P〈0.05）.[结论] 血清CA125水平增高可见于卵巢癌及一些妇科良性疾病;以CA125〈65 kU/L为临界值可显著提高卵巢癌诊断特异性;依据血清CA125水平有利于术前鉴别子宫肌瘤与子宫腺肌症.     

脱落细胞学联合4项肿瘤标志物检测诊断恶性浆膜腔积液的价值

目的探讨脱落细胞学联合癌胚抗原（carcinoembryonic antigen,CEA）、糖链抗原（carbohydrate antigen,CA）125、CA15-3、CA19—9检测对恶性浆膜腔积液的诊断价值。方法比较68例良性浆膜腔积液患者（良性组）和50例恶性浆膜腔积液患者（恶性组）CEA、CA125、CA15-3、CA19—9水平,分析脱落细胞学联合血清肿瘤标志物诊断恶性浆膜腔积液的敏感性、特异性和准确性。结果恶性组脱落细胞学诊断为恶性45例,漏诊5例;良性组脱落细胞学阳性1例,误诊为恶性积液;恶性组CEA、CA125、CA15—3、CA19—9水平均高于良性组（P〈O．01）;脱落细胞学联合4项血清肿瘤标志物诊断恶性浆膜腔积液的敏感性为98％,特异性为98．5％,准确性为98．3％。结论肿瘤标志物联合脱落细胞学检测在浆膜腔积液的良、恶性质判断中有重要价值。     

肾病综合征患者血清CA125升高的相关因素分析

目的 探讨影响肾病综合征患者血清癌抗原-CA125水平升高的相关因素.方法 分别统计入选的83例肾病综合征患者的性别、年龄、体重、血白蛋白、血肌酐、24h尿蛋白定量、浆膜腔积液,采用多元线性逐步回归法、Pearson相关分析及t检验,分析肾病综合征患者血清CA125升高的可能相关因素.结果 血清CA125水平与浆膜腔积液(计分)呈正相关(r=0 588,P<0 05).结论 肾病综合征患者的血清CA125水平升高,可能与浆膜腔积液及低白蛋白血症相关.     

慢性心脏病患者血清CA125水平与心功能的关系

目的观察慢性心脏病患者血清CA125水平的变化与心功能的关系。方法将160例慢性心脏病患者按纽约心功能分级分为心功能Ⅰ-Ⅱ级组（75例）和心功能Ⅲ-Ⅳ级组（85例）。均采用酶联免疫法测定患者血清CA125水平。比较2组患者CA125水平的差异。结果心功能Ⅰ-Ⅱ级组CA125水平为（12.72±14.13）kU.L-1,心功能Ⅲ-Ⅳ级组CA125水平为（89.72±117.66）kU.L-1,2组比较差异有统计学意义（P〈0.01）。结论慢性心脏病患者血清CA125水平随心功能恶化而升高,可作为判断心功能恶化的一项指标。     

系统性红斑狼疮患者CRP水平的分析及临床意义

目的 探讨系统性红斑狼疮（SLE）患者C-反应蛋白（CRP）水平变化及临床意义.方法 回顾性分析2008年8月～2010年8月苏州大学附属第一医院风湿科住院的205例SLE患者,按影像学有无浆膜腔积液表现将其分为有、无浆膜腔积液组,按SLEDAI评分分为有、无活动两组,按统一法获得各观察参数指标数据,分析CRP水平与SLE活动性及浆膜腔积液的关系,并比较分析ESR、C4、C3、IgG与浆膜腔积液的关系.结果 通过分析205例SLE患者,有积液组的CRP水平明显高于无积液组（P〈0.001）,活动组的CRP水平与非活动组无明显差异（P〉0.05）,ESR、C4、C3、IgG与浆膜腔积液无相关（P〉0.05）,通过Logistic回归分析,CRP水平升高与浆膜腔积液的存在有显著相关性（OR= 86.04,95%CI17.85～373,P〈0.001）.结论 SLE患者的CRP水平在反映疾病活动性方面意义不大,但CRP水平升高与浆膜腔积液的存在显著相关.     

脱落细胞学检查与肿瘤标志物检测对恶性浆膜腔积液的诊断价值研究

目的探讨脱落细胞学检测联合肿瘤标志物检测在诊断恶性浆膜腔积液中的应用价值。方法收集2011年1月至2013年1月收治的良性浆膜腔积液患者200例(良性组)和恶性浆膜腔积液患者110例(恶性组),比较两组患者癌胚抗原(CEA)、糖类抗原19-9(CA19-9)及糖类抗原125(CA125)的水平;同时比较恶性组中检出和未检出恶性细胞者血清和积液CEA、CA19-9及CA125水平。结果良性组患者CEA、CA19-9及CA125水平均低于恶性组,差异有统计学意义(P0.05)。恶性组中检出恶性细胞者血清和积液CEA、CA19-9及CA125水平均高于未检出恶性细胞者,差异有统计学意义(P0.05)。结论脱落细胞学联合肿瘤标志物检测在良性和恶性浆膜腔积液鉴别中有重要的临床意义。     

慢性肾衰竭患者血清血管细胞黏附分子-1与血管性假性血友病因子水平变化及临床意义

目的探讨慢性肾衰竭患者血清血管细胞黏附分子-1（VCAM-1）与血管性假性血友病因子（vWF）的变化及临床意义,以及血液透析对其水平的影响。方法应用酶联免疫吸附试验（ELASA）测定30例慢性肾衰竭未透析患者（CRF组）、30例血液透析患者（HD组）、30例健康自愿者（健康对照组）血清VCAM-1与vWF的水平,并比较透析前后的变化。结果 VCAM-1水平在HD组、CRF组及健康对照组分别为（7 638.4±372.2）ng/mL、（6 723.5±136.4）ng/mL、（2 901.3±253.2）ng/mL,HD组、CRF组明显高于健康对照组,差异均有统计学意义（P〈0.01,P〈0.01）。vWF水平在HD组、CRF组以及健康对照组分别为（241.7±13.5）%、（165.6±7.9）%、（90.5±l0.8）%,HD组、CRF组明显高于健康对照组,差异有统计学意义（P〈0.01,P〈0.05）。血清VCAM-1透析后（7 863.4±186.3）ng/mL较透析前（7 638.4±372.2）ng/mL明显升高,差异有统计学意义（P〈0.05）。vWF透析后（291.3±12.6）%较透析前（241.7±13.5）%明显升高,差异有统计学意义（P〈0.05）。结论慢性肾功能衰竭患者及维持性血液透析患者存在血管内皮功能紊乱,血液透析可进一步加重其损害。     

肿瘤标记物在原发性肾脏疾病患者中的血清学浓度改变

目的：了解24h尿蛋白定量、血浆白蛋白、肌酐清除率(Ccr)水平对原发性慢性肾脏病患者血清甲胎蛋白(AFP)、癌胚抗原(CEA)、糖蛋白抗原19-9(CA19-9)和糖蛋白抗原125(CA-125)血清浓度的影响。方法：测定92例非透析慢性肾脏病患者上述4种肿瘤标记物血清浓度．根据其Ccr、24h尿蛋白定量以及血浆白蛋白浓度进行分组，并对数据进行统计学分析。结果：24h尿蛋白定量和血浆白蛋白浓度对血清CA125水平有显著影响，尿蛋白定量增加及血浆白蛋白浓度降低着血清CA125均值升高。不同蛋白尿或Ccr组以上其他3种肿瘤标记物的血浓度无明显差异。结论：尿蛋白定量增加和血浆白蛋白降低的慢性肾病患者．其血浆CA125浓度升高时并不一定提示恶性肿瘤．Ccr、24h尿蛋白定量、血浆白蛋白水平对AFP、CEA、CA19-9无明显影响。     

Serum tumour markers in patients with chronic kidney disease

OBJECTIVE. Tumour markers are widely used for monitoring cancer patients and for screening certain tumours. It has recently been shown that the concentrations of some tumour markers are higher in patients with chronic kidney disease (CKD) than in healthy subjects. We analysed the influence of renal function and hemodialysis treatment on the serum levels of CA19-9, CA125, alpha fetoprotein (AFP), CA15.3, CA72.4, CYFRA 21-1, neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC-Ag). MATERIAL AND METHODS: 232 non-dialysis patients with CKD and 37 uraemic patients treated with maintenance hemodialysis were enrolled in this study. The nondialysis patients were divided into three groups depending on their creatinine clearance (Ccr) levels: group 1 = Ccr < or =25 mL/min; group 2 = 25.1-49.9 mL/min; group 3 = Ccr > or =50 mL/min. For comparison, we chose 37 non-dialysis patients with similar Ccr, age and same gender as controls. RESULTS: The serum concentrations of CA19-9, CA125 (male), CYFRA 21-1, NSE and SCC-Ag correlated negatively with Ccr, while there were no significant differences in the concentrations of CA125 (female), AFP, CA15.3, CA72.4. The serum levels of CA19-9, CA125, AFP, CA15.3, CA72.4, CYFRA 21-1, NSE and SCC-Ag showed no differences between hemodialysis patients and non-dialysis controls (p > 0.017). CONCLUSIONS: The increase in the serum levels of CA19-9, CA125 (in males), CYFRA 21-1, NSE and SCC-Ag in patients with CKD affects the specificity of these markers in the diagnosis of cancer. Hemodialysis does not affect the serum levels of CA19-9, CA125, AFP, CA15.3, CA72.4, CYFRA 21-1, NSE and SCC-Ag.     

CA125监测进展期卵巢癌疗效和复发的意义

目的　评估CA12 5监测进展期卵巢癌疗效及复发的应用价值。方法　采用ES3 0 0全自动酶免疫分析系统检测 5 4例Ⅲ、Ⅳ期原发卵巢癌患者、42例综合治疗后随访卵巢癌患者、2 4例治疗后复发或远处转移患者、15例卵巢良性肿瘤和65例健康女性血清CA12 5水平。结果　 ( 1) 5 4例进展期原发卵巢癌患者血清CA12 5水平显著高于正常人和卵巢良性肿瘤患者。以 3 5U/ml为限定值 ,卵巢上皮癌 10 0 %阳性 ,非上皮癌中 2例内胚窦瘤为阴性 ,其余均阳性。良性肿瘤 13 .3 %假阳性。Ⅲ、Ⅳ期间无显著差异。 ( 2 )原发卵巢癌患者经综合治疗后 ,CA12 5明显下降 ,病情转归与CA12 5下降的幅度相关 ,但与治疗前水平无关。 ( 3 ) 42例随访未出现复发者 ,10 2次检测CA12 5平均值为 2 7.85± 12 .66U /ml ,连续 2次CA12 5升高者 2例 ,治疗后复发或远处转移者 2 4例 ,CA12 5平均值为 3 3 9.5 5± 2 46.6U/ml,其中 95 .8% ( 2 3 /2 4)高于限定值。CA12 5判断复发的准确率为 95 .4% ( 63 /66)。结论　CA12 5的连续监测可作为进展期卵巢癌疗效评价、复发转移及预后的一个有用指标。     

Serum tumour markers in patients with chronic kidney disease

Objective. Tumour markers are widely used for monitoring cancer patients and for screening certain tumours. It has recently been shown that the concentrations of some tumour markers are higher in patients with chronic kidney disease (CKD) than in healthy subjects. We analysed the influence of renal function and hemodialysis treatment on the serum levels of CA19‐9, CA125, alpha fetoprotein (AFP), CA15.3, CA72.4, CYFRA 21‐1, neuron‐specific enolase (NSE) and squamous cell carcinoma antigen (SCC‐Ag). Material and methods. 232 non‐dialysis patients with CKD and 37 uraemic patients treated with maintenance hemodialysis were enrolled in this study. The non‐dialysis patients were divided into three groups depending on their creatinine clearance (Ccr) levels: group 1 = Ccr ?25?mL/min; group 2 = 25.1–49.9?mL/min; group 3 = Ccr ?50?mL/min. For comparison, we chose 37 non‐dialysis patients with similar Ccr, age and same gender as controls. Results. The serum concentrations of CA19‐9, CA125 (male), CYFRA 21‐1, NSE and SCC‐Ag correlated negatively with Ccr, while there were no significant differences in the concentrations of CA125 (female), AFP, CA15.3, CA72.4. The serum levels of CA19‐9, CA125, AFP, CA15.3, CA72.4, CYFRA 21‐1, NSE and SCC‐Ag showed no differences between hemodialysis patients and non‐dialysis controls (p>0.017). Conclusions. The increase in the serum levels of CA19‐9, CA125 (in males), CYFRA 21‐1, NSE and SCC‐Ag in patients with CKD affects the specificity of these markers in the diagnosis of cancer. Hemodialysis does not affect the serum levels of CA19‐9, CA125, AFP, CA15.3, CA72.4, CYFRA 21‐1, NSE and SCC‐Ag.     

胃肠道肿瘤标志物在胰腺癌中的诊断价值

目的探讨血清癌胚抗原(CEA)、癌抗原19-9(CA19-9)、癌抗原125(CA125)、癌抗原724(CA724)、癌抗原50(CA50)对胰腺癌的临床诊断价值。方法用雅培ARCHITECT i2000型化学发光仪检测18例胰腺癌患者、20例胰腺术后患者、15例胰腺炎患者及14例健康体检者血清CEA、CA19-9、CA125、CA724、CA50的含量,胰腺癌组分别与良性病变组和正常对照组比较。结果胰腺癌组中CA19-9、CA125、CEA血清水平较胰腺良性疾病组和健康查体组明显升高,其中以血清CA19-9水平升高最显著。与健康人相比,胰腺良性病组CA19-9、CEA、Ca724升高,差异有统计学意义(P0.05)。而各组CA724未出现统计学差异。CA19-9诊断胰腺癌灵敏度为77.8%,特异度为83.7%,准确率为79.1%。CA19-9+CA125联合检测灵敏度和特异度最高,分别为100%和79.6%,准确率为85.1%。结论血清CA19-9、CEA、CA125在胰腺癌的诊断中有一定的临床应用价值,联合应用可提高胰腺癌的诊断率。     

血清CA125与CA153联合检测对子宫内膜癌的诊断价值

目的 探讨血清CA125、CA153联合检测对子宫内膜癌诊断、预防的临床价值.方法 采用发光免疫分析法对47例子宫内膜癌患者、51例子宫肌瘤患者进行血清CA125、CA153检测,分析两者单独及联合检测对子宫内膜癌诊断的价值.结果 治疗前研究组CA125和CA153水平均显著高于对照组（P＜0.05）;治疗后研究组CA125和CA153水平显著下降,与治疗前相比,差异具有统计学意义（P＜0.05）,其中治疗后研究组与对照组差异无统计学意义（P＞0.05）.无残留癌灶组CA125和CA153水平均明显低于有残留癌灶组（t=2.462,2.786,P＜0.05）.与单项检测相比,联合检测虽然特异性有所降低（χ2=3.372,P＞0.05）,但灵敏度和准确性显著提高（χ2=46.341、52.253,P＜0.05）.结论 CA125和CA153联合检测对鉴别子宫良、恶性疾病和判断预后及复发有重要意义.     

血清四种肿瘤标记物联合检测对肺癌的诊断价值

目的 探讨血清癌胚抗原(CEA)、CA125、CA153、CA199联合检测对肺癌的诊断价值.方法 用化学发光免疫分析法测定58例肺癌患者、38例肺良性病变患者及40名健康体检者血清CEA、CA125、CA153、CA199的含量,评价四项肿瘤标记物联合应用对肺癌的诊断价值.结果 肺癌组的血清CEA、CA125、CA153、CA199含量分别为5.6(1.0～619.0)μg/L、124.5(5.3～994.8)U/ml、14.4(3.1～800.0)U/ml、21.8(2.0～1200.0)U/ml,肺良性病变组分别为1.9(0.6～14.4)μg/L、17.7(1.8～303.6)U/m1、6.8(2.4～20.1)U/ml、9.3(2.0～82.6)U/ml,健康对照组分别为1.4(0.6～5.0)μg/L、9.6(4.4～36.5)U/ml、6.6(3.8～19.9)U/ml、6.4(2.0～58.1)U/ml.肺癌组血清CEA、CA125、CA153、CA199含量明显高于肺良性病变组和健康对照组(P均＜0.01);四项指标联合检测的敏感性为94.8%(55/58),明显高于单一检测[CEA:48.3%(28/58)、CA125:75.9%(44/58)、CA153:20.7%(12/58)、CA199∶31.0%(18/58)].结论 联合检测CEA、CA125、CA153、CA199可提高肺癌的阳性检出率.

Abstract：

Objective To evaluate the clinical value of combined detection of serum CEA, CA125,CA153 and CA199 in lung cancer diagnostec. Methods The serum level of CEA,CA125,CA153 and CA199 in 58 patients with lung cancer,38 patients with benign lung diseases and 40 healthy persons were determinated by Chemiluminesent immunoassay. The data were analyzed to evaluate the diagnostic value of the combination use of four markers. Results The serum levels of CEA,CA125,CA153 and CA199 in lung cancer group were 5.6 (1.0-619. 0) μg/L,124. 5 (5.3 - 994. 8) U/ml,14.4(3. 1 - 800. 0) U/ml and 21.8(2.0 - 1200.0) U/ml respectively ;The serum levels of CEA, CA125, CA153 and CA199 in benign lung diseases were 1.9 (0. 6 -14.4) μg/L, 17. 7 ( 1.8 - 303.6 ) U/ml, 6. 8 ( 2. 4 - 20. 1 ) U/ml and 9. 3 ( 2. 0 - 82. 6 ) U/ml respectively. The serum levels of CEA, CA125, CA153 and CA 199 in healthy controls were 1.4 (0. 6 - 5.0 ) μg/L, 9.6 (4. 4 -36. 5 ) U/ml,6. 6 (3.8 - 19. 9) U/ml and 6. 4 (2.0 - 58. 1 ) U/ml respectively. The levels of markers in the lung cancer group were significantly higher than those in patients with benign lung disease and healthy controllers (Ps ＜ 0. 01 ). The sensitivity of combined measurement was 94. 8%, significantly higher than a single measurement ( CEA 48. 3% ,CA125 75.9% ,CA153 20.7% ,CA199 31.0% ,Ps ＜0. 01 ). Conclusion The combined detection of CEA, CA125, CA153 and CA199 can significantly improve detection sensitivity of lung cancer and might provide valuable laboratory proof for early diagnosis of lung cancer.     

血清CA125和CA199检测对卵巢癌诊断应用价值的探讨

目的：通过测定血清中肿瘤标志物 CA125和 CA199水平,探讨其对卵巢癌诊断的应用价值。方法2011年1月至2012年10月确诊的卵巢癌患者61例,卵巢良性疾病患者68例,健康对照者50例,测定血清中 CA125和CA199水平。结果卵巢癌组血清 CA125和 CA199水平均明显高于卵巢良性疾病组和健康对照组,差异有统计学意义（P ＜0．05）;卵巢良性疾病组血清 CA125和 CA199水平与对照组比较,差异无统计学意义（P ＞0．05）;CA125和CA199联合检测的敏感性明显高于 CA125和 CA199单独检测（P ＜0．05）。结论CA125和 CA199水平进行测定及其联合检测对卵巢癌的诊断、分期和治疗有重要意义。     

Cancer antigen 125 levels in inflammatory bowel diseases

Background: Cancer antigen 125 (CA‐125) is a tumor marker used for the diagnosis and monitoring of ovarian carcinoma. It can also be elevated in endometriosis, inflammations, and in nongynecological malignancies. Up to date, serum CA‐125 levels in inflammatory bowel diseases (IBD) have not been studied before. Aim: To assess the levels of CA‐125 in patients with ulcerative colitis (UC) and Crohn's disease (CD). Methods: Serum levels of CA‐125 were investigated in 68 cases with UC (male/female: 47/21), 32 CD (male/female: 21/11), and 31 healthy controls (male/female: 16/15). Levels of CA‐125 were also compared among UC patients according to lesion location, severity, and activity of CD. Results: Serum CA‐125 levels were 17.29±24.50 U/ml, 15.56±20.74 U/ml, and 8.85±2.62 U/ml in patients with UC, CD, and healthy controls, respectively. Serum CA‐125 levels were significantly higher in UC compared to control group (P=0.001). Serum CA‐125 levels were higher in CD patients compared to control group but there was no significance (P=0.087). Serum CA‐125 levels were higher in pancolitis compared to distal type and left‐sided UC. Conclusions: Our data suggest that serum CA‐125 levels may be increased in patients with IBDs. J. Clin. Lab. Anal. 23:244–248, 2009. © 2009 Wiley‐Liss, Inc.     

血清CA199和CA125联合检测对子宫内膜异位症的诊治意义

[目的]探讨联合检测血清CA199和CA125对诊断子宫内膜异位症及判断病情严重程度的指导意义。[方法]应用微粒子方法检测92例子宫内膜异位症患者血清CA199和CA125指标，并将92例患者依术中所见按美国生育协会（AFS）分期分成Ⅰ、Ⅱ、Ⅲ、Ⅳ4组；按有无并发症和有无其他妇科疾病分别加以研究。[结果]AFS分期越高CA199水平越高。[结论]CA125对子宫内膜异位症有诊断意义，而CA199能提示子宫内膜异位症的严重程度。